Merck & Co., Inc. and Ridgeback Biotherapeutics LP’s COVID-19 pill could face new challenges to its uptake after a new report from a US medical cost-effectiveness watchdog organization has called its overall benefit into question. The Institute for Clinical and Economic Review (ICER) had earlier indicated Lagevrio (molnupiravir) appeared to be cost effective, but its advisory committee questioned the benefit it offers.
ICER Gives Cold Shoulder To Merck/Ridgeback’s COVID-19 Pill
Group’s final report said evidence was inadequate to demonstrate a net health benefit versus symptomatic care for Lagevrio, a drug that has already taken a back seat to Pfizer’s Paxlovid.
